ArticleFrontiers in medicine2026
Expression levels of serum SCC, HE4, and TSGF in cervical cancer patients and their correlation with recurrence: a retrospective study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective study aimed to evaluate the utility of combining pretreatment serum tumor markers with clinicopathological features for predicting recurrence risk in patients with cervical cancer. Methods: The analysis included 107 patients with pathologically confirmed cervical cancer who completed initial treatment. Based on recurrence within 3 years, patients were categorized into recurrence ( Results: Pretreatment serum SCC, HE4, TSGF, SCC/HE4 ratio, and LogitScore were significantly higher in the recurrence group. Post-treatment declines in these markers were more pronounced in the non-recurrence group. The recurrence group had a higher prevalence of advanced FIGO stage (III-IV), larger tumor diameter (>4 cm), lymph node metastasis, and lymphovascular space invasion. These tumor marker levels correlated positively with adverse pathological features. The composite LogitScore demonstrated the highest area under the ROC curve (0.983) for predicting recurrence. Multivariate analysis established FIGO stage III-IV, HE4 > 140 pmol/L, and a high-risk LogitScore as independent risk factors for shorter RFS. Conclusion: The combination of pretreatment serum HE4, a composite LogitScore, and FIGO stage represents a promising indicator set for predicting cervical cancer recurrence in this exploratory, internally validated analysis. This model, developed and evaluated within the same cohort, shows potential clinical value for early identification of high-risk patients, though its performance requires further validation in independent external cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.